These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15450337)

  • 21. Alefacept for the treatment of psoriasis and other dermatologic diseases.
    Strober BE; Menon K
    Dermatol Ther; 2007; 20(4):270-6. PubMed ID: 17970892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alefacept (Amevive) for treatment of psoriasis.
    Med Lett Drugs Ther; 2003 Apr; 45(1154):31-2. PubMed ID: 12717339
    [No Abstract]   [Full Text] [Related]  

  • 23. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study.
    Strober BE; Menon K; McMichael A; Hordinsky M; Krueger G; Panko J; Siu K; Lustgarten JL; Ross EK; Shapiro J
    Arch Dermatol; 2009 Nov; 145(11):1262-6. PubMed ID: 19917955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
    Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
    J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and use of alefacept to treat psoriasis.
    Krueger GG; Callis KP
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on alefacept safety.
    Wexler D; Searles G; Landells I; Shear NH; Bissonnette R; Papp K; Poulin Y; Langley R; Gulliver WP
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S139-47. PubMed ID: 20053326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
    Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
    J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alefacept modifies long-term disease severity and improves the response to other treatments.
    van Duijnhoven MW; de Jong EM; Gerritsen WJ; Pasch MC; van de Kerkhof PC
    Eur J Dermatol; 2005; 15(5):366-73. PubMed ID: 16172047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of alefacept in elderly patients and other special populations.
    Gottlieb AB; Boehncke WH; Darif M
    J Drugs Dermatol; 2005; 4(6):718-24. PubMed ID: 16302557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
    Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
    Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
    Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC
    J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
    Ortonne JP; Lebwohl M; Em Griffiths C;
    Eur J Dermatol; 2003; 13(2):117-23. PubMed ID: 12695125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
    Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
    Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current concepts and review of pimecrolimus in the treatment of psoriasis.
    Wolff K
    Dermatol Clin; 2004 Oct; 22(4):461-5, ix-x. PubMed ID: 15450341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis.
    Prossick TA; Belsito DV
    Cutis; 2006 Sep; 78(3):178-80. PubMed ID: 17036660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
    Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
    J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of palmoplantar psoriasis with intramuscular alefacept.
    Myers W; Christiansen L; Gottlieb AB
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
    Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
    J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting T-cell subsets to achieve remission.
    Christophers E
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():6-11. PubMed ID: 12795769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.